ClinicalRM awarded BARDA contract to support medical countermeasures clinical studies network

With this contract award ClinicalRM becomes part of a clinical studies network being established by BARDA to support development of vaccines, drugs, and diagnostics, known as medical countermeasures, needed to protect health and potentially save lives in public health emergencies.

The network will provide clinical services in support of adequate and well-controlled Phase I through IV clinical trials or trials during a public health emergency, and will support the evaluation of chemical, biological, radiological, nuclear, pandemic influenza and emerging infectious disease medical countermeasures.

ClinicalRM is one of only five other companies to be awarded this contract. 100% of the total costs of the program will be financed with Federal money. It is a two-year contract with three one-years option BARDA may exercise. The total contract ceiling for five-year program is $100m.

ClinicalRM program director Dr David Hoover noted it looks forward to working with BARDA to evaluate new treatments for medical conditions that could have devastating impacts on many people.

"New treatments are vitally important for improved management of infectious diseases and exposures to a broad range of toxic agents," Dr Hoover added.